TY - JOUR
T1 - Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder
T2 - An empirical evaluation of olanzapine, risperidone, and quetiapine
AU - Byerly, Matthew J.
AU - Nakonezny, Paul A.
AU - Bettcher, Brianne Magouirk
AU - Carmody, Thomas
AU - Fisher, Robert
AU - Rush, A. John
N1 - Funding Information:
This study was supported by NIMH K-Award grant # 5 K23 MH064930, the Stanley Medical Research Institute, and the Betty Jo Hay Distinguished Chair in Mental Health.
PY - 2006/9
Y1 - 2006/9
N2 - Objective: Evaluate sexual dysfunction, as measured by the Arizona Sexual Experience Scale (ASEX), in olanzapine-, quetiapine-, and risperidone-treated outpatients with schizophrenia or schizoaffective disorder. Method: The sexual functioning of 238 outpatients (age ≥ 18 years) with diagnoses of schizophrenia or schizoaffective disorder who took quetiapine (n = 57), olanzapine (n = 94), or risperidone (n = 87) was evaluated with a one-time rating of the ASEX. The dose range for each treatment group was 5 to 40 mg/day (M = 16.6 mg/day, SD = 7.4) for olanzapine; 1 to 8 mg/day (M = 3.9 mg/day, SD = 1.6) for risperidone; and 50 to 900 mg/day (M = 376.8 mg/day, SD = 213.4) for quetiapine. Antipsychotic group designation was based on medication treatment at study entry (i.e., non-random assignment). Participant characteristics were collected to test for treatment group differences and for potential associations with severity of sexual dysfunction. The primary data analysis was a mixed linear model analysis of covariance with age, gender, and presence/absence of antidepressant known to cause sexual dysfunction included as covariates. Results: There was a significant treatment effect on severity of sexual dysfunction, as measured by ASEX total scores (p = .04). The adjusted average ASEX total scores were lower in the quetiapine (M = 17.80) than in the risperidone (M = 19.69) or olanzapine (M = 20.34) groups. Individual comparisons of the treatments on adjusted average ASEX total scores indicated a significant difference between olanzapine and quetiapine (p = .04), but no difference between risperidone and quetiapine (p = .17) or olanzapine and risperidone (p = .76). Conclusions: Quetiapine was associated with less severe sexual dysfunction than olanzapine and risperidone (albeit the effect between risperidone and quetiapine was not statistically significant). Olanzapine and risperidone were associated with a comparable degree of sexual dysfunction. Patients in all three treatment groups, nonetheless, experienced a moderately high degree of sexual dysfunction. Because the patients were not randomized, conclusions must be interpreted within the context of the quasi-experimental design.
AB - Objective: Evaluate sexual dysfunction, as measured by the Arizona Sexual Experience Scale (ASEX), in olanzapine-, quetiapine-, and risperidone-treated outpatients with schizophrenia or schizoaffective disorder. Method: The sexual functioning of 238 outpatients (age ≥ 18 years) with diagnoses of schizophrenia or schizoaffective disorder who took quetiapine (n = 57), olanzapine (n = 94), or risperidone (n = 87) was evaluated with a one-time rating of the ASEX. The dose range for each treatment group was 5 to 40 mg/day (M = 16.6 mg/day, SD = 7.4) for olanzapine; 1 to 8 mg/day (M = 3.9 mg/day, SD = 1.6) for risperidone; and 50 to 900 mg/day (M = 376.8 mg/day, SD = 213.4) for quetiapine. Antipsychotic group designation was based on medication treatment at study entry (i.e., non-random assignment). Participant characteristics were collected to test for treatment group differences and for potential associations with severity of sexual dysfunction. The primary data analysis was a mixed linear model analysis of covariance with age, gender, and presence/absence of antidepressant known to cause sexual dysfunction included as covariates. Results: There was a significant treatment effect on severity of sexual dysfunction, as measured by ASEX total scores (p = .04). The adjusted average ASEX total scores were lower in the quetiapine (M = 17.80) than in the risperidone (M = 19.69) or olanzapine (M = 20.34) groups. Individual comparisons of the treatments on adjusted average ASEX total scores indicated a significant difference between olanzapine and quetiapine (p = .04), but no difference between risperidone and quetiapine (p = .17) or olanzapine and risperidone (p = .76). Conclusions: Quetiapine was associated with less severe sexual dysfunction than olanzapine and risperidone (albeit the effect between risperidone and quetiapine was not statistically significant). Olanzapine and risperidone were associated with a comparable degree of sexual dysfunction. Patients in all three treatment groups, nonetheless, experienced a moderately high degree of sexual dysfunction. Because the patients were not randomized, conclusions must be interpreted within the context of the quasi-experimental design.
KW - Antipsychotics
KW - Schizophrenia
KW - Sexual dysfunction
UR - http://www.scopus.com/inward/record.url?scp=33747184801&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33747184801&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2006.04.005
DO - 10.1016/j.schres.2006.04.005
M3 - Article
C2 - 16730951
AN - SCOPUS:33747184801
SN - 0920-9964
VL - 86
SP - 244
EP - 250
JO - Schizophrenia Research
JF - Schizophrenia Research
IS - 1-3
ER -